Scarica l'app Stockscreener
2.01
11.05%
0.20
Dopo l'orario di chiusura:
1.99
-0.02
-1.00%
Precedente Chiudi:
$1.81
Aprire:
$1.81
Volume 24 ore:
1.76M
Relative Volume:
1.07
Capitalizzazione di mercato:
$220.52M
Reddito:
-
Utile/perdita netta:
$-134.24M
Rapporto P/E:
-1.1356
EPS:
-1.77
Flusso di cassa netto:
$-121.34M
1 W Prestazione:
+25.62%
1M Prestazione:
+40.56%
6M Prestazione:
-67.16%
1 anno Prestazione:
-53.90%
Intervallo 1D:
$1.795
$2.05
Intervallo di 1 settimana:
$1.67
$2.05
Portata 52W:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Nome
Annexon Inc
Settore
Industria
Telefono
(650)-822-5500
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Confronta ANNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.01 | 175.54M | 0 | -134.24M | -121.34M | -1.77 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-30 | Iniziato | Wells Fargo | Overweight |
| 2023-05-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | BTIG Research | Buy |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Annexon Inc Borsa (ANNX) Ultime notizie
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon (ANNX) Advances with Promising Neurological and Vision T - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Positi - GuruFocus
Annexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic Diseases - Nasdaq
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
Hsbc Holdings PLC Has $156,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Dimensional Fund Advisors LP Buys 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon Announces Presentations on the Clinical Advancement - GlobeNewswire
Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday - Defense World
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting | ANNX Stock News - GuruFocus
Annexon, Inc. Reports Improved Outcomes for Tanruprubart in Guillain-Barré Syndrome at 2025 Peripheral Nerve Society Annual Meeting - Nasdaq
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - Stock Titan
Annexon Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress - The Manila Times
Annexon to Present on the Neuroprotective Effects of ANX007 - GlobeNewswire
MetLife Investment Management LLC Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Barclays PLC - Defense World
Annexon Biosciences wants to Move GBS Forward in awareness push - Medical Marketing and Media
Invesco Ltd. Acquires 10,611 Shares of Annexon, Inc. (NASDAQ:ANNX) - The AM Reporter
Holdings of Annexon Inc (ANNX) are aligned with the stars - Sete News
What technical indicators reveal about ANNX stock - uspostnews.com
JP Morgan’s latest rating for ANNX stock - knoxdaily.com
Analytical Overview: Annexon Inc (ANNX)’s Ratios Tell a Financial Story - DWinneX
Legal & General Group Plc Acquires 71,665 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Wells Fargo & Company MN Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Investors in cash trouble should check out Annexon Inc (ANNX) - Sete News
SEC Form DEFA14A filed by Annexon Inc. - Quantisnow
JP Morgan analysts upgrades an Overweight rating for Annexon Inc (ANNX) - knoxdaily.com
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - Defense World
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Annexon Inc (ANNX) Stock: A Year of Market Fluctuations - investchronicle.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc Azioni (ANNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Annexon Inc Azioni (ANNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):